The "metabolovirus" model of hepatitis B virus suggests nutritional therapy as an effective anti-viral weapon

Medical Hypotheses

Volumn 71, Issue 1, 2008, Pages 53-57

  Shlomai, Amir ^a   Shaul, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARBOHYDRATE INTAKE; DIET THERAPY; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE SYSTEM; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS RESISTANCE;

GENE EXPRESSION; GENES, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER; MODELS, BIOLOGICAL; NUTRITION THERAPY;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 43949084684     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.08.032     Document Type: Article

References (23)

1. Ganem D., and Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
2. Shaul Y., Rutter W.J., and Laub O. A human hepatitis B viral enhancer element. EMBO J 4 (1985) 427-430
3. Tang H., and McLachlan A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. PNAS 98 (2001) 1841-1846
4. Tang H., Raney A.K., and McLachlan A. Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture. J Virol 75 (2001) 8937-8948
5. Yu X., and Mertz J.E. Differential regulation of the pre-C and pregenomic promoters of human hepatitis B virus by members of the nuclear receptor superfamily. J Virol 71 (1997) 9366-9374
6. Doitsh G., and Shaul Y. Enhancer I predominance in hepatitis B virus gene expression. Mol Cell Biol 24 (2004) 1799-1808
7. Gupta R.K., and Kaestner K.H. HNF-4[alpha]: from MODY to late-onset type 2 diabetes. Trends Mol Med 10 (2004) 521-524
8. Rhee J., Inoue Y., Yoon J.C., et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. PNAS 100 (2003) 4012-4017
9. Yoon J.C., Puigserver P., Chen G., et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413 (2001) 131-138
10. Shlomai A., Paran N., and Shaul Y. PGC-1{alpha} controls hepatitis B virus through nutritional signals. PNAS 103 (2006) 16003-16008
11. Koo S.H., Flechner L., Qi L., et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437 (2005) 1109-1111
12. Jones R.G., Plas D.R., Kubek S., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18 (2005) 283-293
13. Chang J.J., and Lewin S.R. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 85 (2006) 16-23
14. David Milich T.J.L. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38 (2003) 1075-1086
15. Wijnen H., and Young M.W. Interplay of circadian clocks and metabolic rhythms. Annu Rev Genet 40 (2006) 409-448
16. Liu C., Li S., Liu T., Borjigin J., and Lin J.D. Transcriptional coactivator PGC-1[agr] integrates the mammalian clock and energy metabolism. Nature 447 (2007) 477-481
17. Collaco A., Rahman S., Dougherty E., Williams B., and Geusz M. Circadian regulation of a viral gene promoter in live transgenic mice expressing firefly luciferase. Mol Imag Biol 7 (2005) 342-350
18. Shadan F.F. A circadian model for viral persistence. Med Hypoth 68 (2007) 546-553
19. Evans A.A., O'Connell A.P., Pugh J.C., et al. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 7 (1998) 559-565
20. Hu J.F., Cheng Z., Chisari F.V., Vu T.H., Hoffman A.R., and Campbell T.C. Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet. Oncogene 15 (1997) 2795-2801
21. Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of lamivudine prophylaxis. Cancer Invest 24 (2006) 548-552
22. Lalazar G., Rund D., and Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136 (2007) 699-712
23. Vassiliadis T., Garipidou V., Tziomalos K., Perifanis V., Giouleme O., and Vakalopoulou S. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy - a prospective case series. Am J Hematol 80 (2005) 197-203